# **Mechanistic Analysis of Systemic Feedback Loops and Enzymatic Regulation Following Oral Nicotinamide Mononucleotide Administration**

## **Thermodynamic and Kinetic Foundations of Nicotinamide Adenine Dinucleotide Homeostasis**

The preservation of nicotinamide adenine dinucleotide (![][image1]) concentrations is an absolute requirement for the maintenance of cellular viability across all mammalian species. As a quintessential coenzyme, ![][image1] facilitates hundreds of redox reactions, serving as a hydride acceptor in catabolic pathways such as glycolysis, the tricarboxylic acid (TCA) cycle, and ![][image2]\-oxidation.1 Beyond its role in energy transduction, ![][image1] acts as a critical substrate for several families of signaling enzymes, most notably sirtuins, poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose hydrolases like CD38 and CD157.3 These enzymes consume ![][image1] to mediate protein deacetylation, DNA repair, and calcium signaling, respectively, yielding nicotinamide (NAM) as a metabolic byproduct.5

The continuous turnover of ![][image1] necessitates a robust and highly regulated biosynthetic infrastructure. In mammals, ![][image1] is synthesized through three primary routes: the de novo kynurenine pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid (NA), and the salvage pathway from NAM.2 The salvage pathway is the most prolific, accounting for approximately 85% of daily ![][image1] synthesis, as it allows for the recycling of NAM produced by ![][image1]\-consuming enzymes.8 The rate-limiting step of this salvage mechanism is governed by the enzyme nicotinamide phosphoribosyltransferase (NAMPT), which converts NAM and 5-phosphoribosyl-1-pyrophosphate (PRPP) into nicotinamide mononucleotide (NMN).3

Given that NAMPT sits at the apex of ![][image1] flux regulation, the introduction of exogenous NMN through oral supplementation poses a fundamental biological question: Does the bypass of this rate-limiting step lead to a compensatory downregulation of endogenous enzymatic production or activity? The inherent complexity of this feedback loop involves not only the kinetic inhibition of existing enzymes but also the potential for long-term genetic and proteomic shifts in response to a sustained surplus of downstream metabolites.11

## **Structural Biology and Regulatory Domains of NAMPT**

NAMPT exists as a homodimeric protein where the active sites are located at the interface of the two monomers.10 The catalytic mechanism is highly sophisticated, involving the ATP-dependent phosphorylation of a specific histidine residue (His-247), which enhances the enzyme's affinity for its substrates.10 The structural architecture of NAMPT includes three distinct domains relevant to its regulation: the active site, the nucleobase pocket, and a "rear channel".3

### **The Mechanics of Product and Substrate Inhibition**

NAMPT activity is meticulously controlled by its own products through a mechanism of feedback inhibition. Both NMN and ![][image1] act as autoinhibitors, binding to the enzyme to prevent the excessive accumulation of ![][image1].3 This self-regulation ensures that the cellular ![][image3] ratio remains within a range compatible with mitochondrial health and metabolic homeostasis.2

| Component | Role in NAMPT Regulation | Impact of Increased NMN Levels |
| :---- | :---- | :---- |
| Nicotinamide (NAM) | Primary substrate | Displaced from active site by high NMN concentrations |
| PRPP | Necessary co-substrate | Availability potentially spared for nucleotide synthesis |
| ATP | Catalytic activator | Required for His-247 phosphorylation; demand remains constant |
| NMN | Primary product | High levels competitively inhibit NAM binding; direct feedback |
| ![][image1] | Distal product | Acts as an allosteric or product inhibitor at high concentrations |

The binding of NMN to the NAMPT active site occupies the nucleobase pocket, effectively blocking the entry of NAM.11 Consequently, when oral NMN is administered and successfully transported into the intracellular environment, the endogenous conversion of NAM to NMN is significantly curtailed.10 This phenomenon represents a direct, kinetic downregulation of endogenous "production" flux, although it does not necessarily imply an immediate reduction in the physical concentration of the NAMPT enzyme itself.7

### **Allosteric Modulation and the Rear Channel**

A critical insight into NAMPT regulation has emerged from the study of its "rear channel," which extends from the active site to the protein surface.3 This channel is the target site for NAMPT positive allosteric modulators (N-PAMs) and certain "boosters".3 These molecules can relieve product inhibition by altering the enzyme's conformation, thereby increasing the turnover rate of NAM to NMN even when intracellular NMN or ![][image1] levels are high.3 This suggests that the body's natural downregulation of NAMPT in response to NMN is not an immutable state but a sensitive equilibrium that can be pharmacologically manipulated.3

## **Impact of Oral NMN Intake on NAMPT Expression and Proteomic Levels**

The investigation into whether long-term NMN supplementation reduces the mRNA expression or protein levels of NAMPT has yielded nuanced results that differ based on the age and physiological state of the organism.12

### **Restoration vs. Downregulation in Aging Models**

During the normal aging process, the expression of NAMPT and the levels of ![][image1] are known to decline significantly across diverse tissues, including the liver, adipose tissue, and skeletal muscle.7 This decline is often driven by "inflammaging," where pro-inflammatory cytokines such as ![][image4] and ![][image5] suppress NAMPT expression.4 Studies in aged mice have shown that NMN supplementation can mitigate some of these age-associated changes.6

In a 12-month chronic administration study in mice, NMN in drinking water was found to prevent the age-associated decline in ![][image1] levels and the accompanying changes in gene expression in key metabolic organs.15 In the skeletal muscle of these mice, NMN actually enhanced mitochondrial oxidative metabolism and influenced the mitonuclear protein balance, suggesting that the exogenous precursor was working in tandem with the endogenous system to restore a more youthful metabolic state.15 There was no evidence of a systemic collapse or compensatory permanent downregulation of the NAMPT protein as a result of the 12-month exposure.15

### **Feedback Regulation in Pathological States**

Conversely, in specific disease contexts where NAMPT is pathologically upregulated, NMN supplementation has demonstrated a capacity for downregulation. In models of diabetic nephropathy (DN), endogenous Nampt is often elevated, where it functions as a pro-inflammatory cytokine—historically referred to as visfatin—promoting glomerular fibrosis and inflammation.12 In these instances, treatment with NMN has been shown to inhibit this endogenous upregulation of Nampt, thereby alleviating inflammatory-fibrosis through the modulation of the ![][image6] p65 and SIRT1 pathways.12 This indicates that NMN can act as a homeostatic regulator, downregulating enzymatic production when it becomes excessive or deleterious, while restoring it when it is deficient due to age.12

## **Secondary Metabolic Productions Subject to Regulation and Drain**

The ingestion of NMN triggers a cascade of metabolic shifts that influence several other enzymatic systems, some of which may experience a form of "drain" or altered production dynamics.

### **Nicotinamide N-Methyltransferase (NNMT) and Methyl Donor Consumption**

A significant concern in ![][image1] precursor research is the impact on the body's methyl pool. When ![][image1] is consumed by enzymes such as sirtuins or CD38, NAM is released.1 If the salvage pathway (via NAMPT) is inhibited by high NMN levels, or if the influx of NAM exceeds the salvage capacity, the excess NAM must be excreted.8 This excretion process is facilitated by nicotinamide N-methyltransferase (NNMT), which methylates NAM to 1-methylnicotinamide (MNAM) using S-adenosylmethionine (SAM) as the methyl donor.19

![][image7]  
Continuous high-dose NMN intake can lead to an upregulation of NNMT activity to manage the NAM surge.4 This has several potential consequences:

1. **Methyl Donor Depletion**: The excessive consumption of SAM can deplete the universal methyl donor pool, potentially interfering with DNA methylation and other epigenetic regulations.21  
2. **Homocysteine Elevation**: The conversion of SAM to S-adenosylhomocysteine (SAH) and subsequently to homocysteine can increase cardiovascular risk factors if not managed by adequate intake of folate, ![][image8], or trimethylglycine (TMG).19

| Metabolic Marker | Change Following NMN Intake | Physiological Implication |
| :---- | :---- | :---- |
| Nicotinamide (NAM) | Increase (due to ![][image1] turnover) | Substrate for excretion or salvage |
| MNAM | Significant Increase | Product of NNMT activity; excreted in urine |
| SAM | Potential Decrease | Risk of methyl donor depletion for DNA repair |
| SAH / Homocysteine | Potential Increase | Marker of methylation stress and vascular risk |
| SIRT1 Activity | Increase | Enhanced protein deacetylation and longevity signaling |

### **CD38-Mediated Base Exchange and Deamidated Metabolites**

The enzyme CD38 is a major consumer of ![][image1], but it also exhibits complex interactions with NMN.23 CD38 can function as an NMN glycohydrolase, breaking it down into NAM and ribose-5-phosphate.23 Furthermore, research has revealed that CD38 can catalyze a "base exchange" reaction on NMN.24 In this process, the nicotinamide ring of NMN is exchanged with free nicotinic acid to yield nicotinic acid mononucleotide (NaMN), an intermediate of the Preiss-Handler pathway.24

This suggests that NMN supplementation may inadvertently "produce" or elevate levels of deamidated intermediates like NaMN and NaAD, which were traditionally thought to reside in independent biosynthetic pathways.24 This crossover between amidated and deamidated pathways highlights a sophisticated biological strategy to diversify the ![][image1] precursor pool, but it also means that NMN intake downregulates the "purity" of the salvage-only route in favor of a more distributed metabolic network.9

## **Human Clinical Observations and Individual Variability**

The translation of these biochemical mechanisms into human health outcomes has been evaluated through multiple randomized clinical trials.16 These studies generally confirm that oral NMN is safe and effectively increases blood ![][image1] levels, but they also highlight a significant degree of variability in how individuals "produce" ![][image1] from NMN.5

### **Clinical Efficacy and Dosing Metrics**

Trials involving middle-aged and older adults have shown that ![][image1] levels typically peak after 30 to 60 days of daily supplementation.25 The magnitude of the increase is dose-dependent, with the highest efficacy observed at doses of 600 mg to 900 mg per day.16

| Study Parameter | Placebo Group | 300 mg NMN | 600 mg NMN | 900 mg NMN |
| :---- | :---- | :---- | :---- | :---- |
| Blood ![][image1] Change (Day 60\) | Minimal (+14.3%) | Significant (\~11-20%) | Peak (\~38%) | Plateau (\~38%) |
| 6-Minute Walk Distance | No Change | Improved | Most Improved | Most Improved |
| SF-36 Health Score | No Change | Significant Improvement | Significant Improvement | Significant Improvement |
| Biological Age Change | Increased | Stable | Stable | Stable |

The data indicates that while ![][image1] levels increase, there is a large inter-individual variation (coefficient of variation between 29% and 113%).25 This variability is likely due to differences in gut microbiota (which can deamidate NMN), baseline NAMPT activity, and the expression levels of NMN transporters like Slc12a8 in the small intestine.5

### **Post-Supplementation Washout and Recovery**

A critical area of concern for users is whether the body "forgets" how to make ![][image1] after stopping NMN. Clinical protocols using washout periods of 14 to 21 days have provided essential data on this.28 In a 12-week study, blood ![][image1] levels were found to return to their original baseline within 4 weeks of treatment cessation.16

Importantly, there is no evidence of a "rebound effect" or a decrease below the original baseline, which would indicate a permanent downregulation of endogenous production.29 The fatigue sometimes reported after stopping is characterized not as a withdrawal or a crash but as a return to the body's baseline fuel status.29 The "NAD World" appears robust enough to resume its natural pace of synthesis once the exogenous supply is removed.29

## **Paradoxical Downregulations and Tissue-Specific Risks**

While the metabolic benefits of NMN are well-documented, specific contexts reveal that "more" is not always "better," and high-dose intake can lead to certain deleterious downregulations in sensitive tissues.

### **Renal Susceptibility and Inflammation in Late-Stage Aging**

In experiments with very old mice (26 months), long-term high-dose NMN supplementation (300 mg/kg) unexpectedly exacerbated renal inflammation.30 This was marked by an increase in uremic toxins and the upregulation of markers for tubule injury such as ![][image9] and pro-inflammatory cytokines like ![][image5].30

This suggests that in the presence of pre-existing mitochondrial dysfunction (common in aged kidneys), the sudden surge in ![][image1] flux may not be efficiently utilized and can instead trigger inflammatory pathways.30 In this context, NMN "downregulates" renal health, highlighting that the benefits of supplementation are highly context-dependent and may require lower doses or synergistic interventions (like the mitochondrial peptide elamipretide) in the elderly.30

### **Reproductive Health and Oxidative Stress**

The impact of NMN on fertility and reproductive outcomes is equally complex. While oral NMN has been shown to improve oocyte quality and restore mitochondrial function in the ovaries of aged mice, other modes of administration have shown different results.17 For instance, high-dose intraperitoneal injection of NMN in certain models resulted in elevated oxidative stress in sperm and a decline in quality.32 However, these negative effects were not observed with oral administration, suggesting that the rate and route of absorption play a decisive role in whether NMN supports or downregulates healthy cellular function.32

## **The Integrated "NAD World" and Future Regulatory Insights**

The regulation of ![][image1] through NMN is not a closed loop but a systemic network known as the "NAD World".6 This concept emphasizes the communication between the hypothalamus (the control center) and peripheral tissues like adipose and liver.13

### **eNAMPT and Extracellular Signaling**

The extracellular form of NAMPT (eNAMPT) is actively secreted by adipocytes and circulates in the plasma, often encapsulated in extracellular vesicles (EVs).6 eNAMPT has higher enzymatic activity than its intracellular counterpart and is crucial for maintaining hypothalamic ![][image1] levels and biological robustness.6 NMN supplementation interacts with this system by providing the product of eNAMPT directly to target tissues.6 This suggests that oral NMN can compensate for the age-related decline in eNAMPT, effectively "upregulating" the systemic communication network even if local intracellular NAMPT is kinetics-limited.6

### **Conclusion on Enzymatic Downregulation**

The evidence synthesized from structural biology, animal models, and human trials suggests that oral NMN intake does indeed induce a **kinetic downregulation** of endogenous NAMPT activity through product inhibition.11 However, this is a part of the enzyme's natural homeostatic design to prevent metabolite overflow.10 Crucially, there is no significant evidence that NMN supplementation leads to a **permanent or deleterious downregulation** of NAMPT protein expression in healthy or aging subjects.15 Instead, in most contexts of aging and metabolic disease, NMN acts to restore a declining system to its homeostatic norm.12

The primary regulatory risks identified include the **drain on the methyl pool** (via NNMT) and the **potential for renal inflammation** in late-stage aging, both of which require careful dosing and potentially the co-administration of methyl donors.20 Ultimately, NMN supplementation appears to be a robust tool for metabolic support, where the body's internal feedback loops act as a guide for homeostasis rather than a barrier to therapeutic efficacy.13

#### **Works cited**

1. NAD+ metabolism and its roles in cellular processes during ageing \- PMC \- PubMed Central, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/)  
2. The role of NAD+ metabolism and its modulation of mitochondria in aging and disease, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/)  
3. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death | Journal of Medicinal Chemistry \- ACS Publications, accessed January 23, 2026, [https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02112](https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02112)  
4. The Central Role of the NAD+ Molecule in the Development of Aging and the Prevention of Chronic Age-Related Diseases: Strategies for NAD+ Modulation \- MDPI, accessed January 23, 2026, [https://www.mdpi.com/1422-0067/24/3/2959](https://www.mdpi.com/1422-0067/24/3/2959)  
5. Nicotinamide Mononucleotide Supplementation: Understanding ..., accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11205942/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11205942/)  
6. The Science Behind NMN–A Stable, Reliable NAD+Activator and Anti-Aging Molecule \- NIH, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7238909/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7238909/)  
7. Nicotinamide phosphoribosyltransferase in NAD+ metabolism ..., accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12332177/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12332177/)  
8. Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications \- MDPI, accessed January 23, 2026, [https://www.mdpi.com/2218-1989/14/6/341](https://www.mdpi.com/2218-1989/14/6/341)  
9. The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications \- Frontiers, accessed January 23, 2026, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1436597/full](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1436597/full)  
10. A mechanism of allosteric modulation of nicotinamide phosphoribosyltransferase to elevate cellular NAD+ \- PMC \- PubMed Central, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10935581/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10935581/)  
11. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to ..., accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11056997/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11056997/)  
12. Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory-fibrosis through the NF-κB p65 and Sirt1 pathway \- NIH, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5658765/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5658765/)  
13. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and aging \- PMC \- PubMed Central, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3819727/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3819727/)  
14. Nicotinamide Mononucleotide, an NAD+ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1–Dependent Manner, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5533221/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5533221/)  
15. Long-term administration of nicotinamide mononucleotide mitigates ..., accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5668137/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5668137/)  
16. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial \- PMC \- NIH, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/)  
17. Use of the Dietary Supplements NR and NMN to Increase Nicotinamide Adenine Dinucleotide, Impact Mitochondrial Function, and Improve Metabolic Health \- MDPI, accessed January 23, 2026, [https://www.mdpi.com/3042-5158/1/2/9](https://www.mdpi.com/3042-5158/1/2/9)  
18. Nicotinamide phosphoribosyltransferase postpones rat bone marrow mesenchymal stem cell senescence by mediating NAD+–Sirt1 signaling \- PMC \- NIH, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6594813/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6594813/)  
19. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme \- PMC, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5446048/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5446048/)  
20. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome \- PMC \- PubMed Central, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11196770/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11196770/)  
21. Do I need to take methyl donors with my NMN? \- NOVOS, accessed January 23, 2026, [https://novoslabs.com/frequently-asked-questions/nmn-nicotinamide-mononucleotide/do-i-need-to-take-methyl-donors-with-my-nmn/](https://novoslabs.com/frequently-asked-questions/nmn-nicotinamide-mononucleotide/do-i-need-to-take-methyl-donors-with-my-nmn/)  
22. Advanced NAD⁺ Therapies & Precursors: Beyond NR & NMN \- Redox Medical Group, accessed January 23, 2026, [https://redoxmedicalgroup.com/advanced-nad%E2%81%BA-therapies-precursors-beyond-nr-nmn/](https://redoxmedicalgroup.com/advanced-nad%E2%81%BA-therapies-precursors-beyond-nr-nmn/)  
23. CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism \- PMC \- NIH, accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4911708/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911708/)  
24. CD38 mediates nicotinamide mononucleotide (NMN) base exchange to yield nicotinic acid ... \- bioRxiv, accessed January 23, 2026, [https://www.biorxiv.org/content/10.1101/2024.08.08.607247v1.full-text](https://www.biorxiv.org/content/10.1101/2024.08.08.607247v1.full-text)  
25. Towards personalized nicotinamide mononucleotide (NMN) supplementation: nicotinamide adenine dinucleotide (NAD) concentration | medRxiv, accessed January 23, 2026, [https://www.medrxiv.org/content/10.1101/2024.02.19.24303025v1.full-text](https://www.medrxiv.org/content/10.1101/2024.02.19.24303025v1.full-text)  
26. Nicotinamide Mononucleotide: Deciphering Metabolic Complexities for Improved Health Outcomes \- Preprints.org, accessed January 23, 2026, [https://www.preprints.org/manuscript/202403.1752/v1](https://www.preprints.org/manuscript/202403.1752/v1)  
27. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults \- Frontiers, accessed January 23, 2026, [https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2022.851698/full](https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2022.851698/full)  
28. Study Details | NCT05698771 | NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy | ClinicalTrials.gov, accessed January 23, 2026, [https://www.clinicaltrials.gov/study/NCT05698771](https://www.clinicaltrials.gov/study/NCT05698771)  
29. Why People Stop Taking NMN: A Clinical Review of NAD Supplement Side Effects, accessed January 23, 2026, [https://www.perfectb.com/why-people-stop-taking-nmn-a-clinical-review-of-nad-supplement-side-effects/](https://www.perfectb.com/why-people-stop-taking-nmn-a-clinical-review-of-nad-supplement-side-effects/)  
30. Metabolite accumulation from oral NMN supplementation drives aging-specific kidney inflammation | bioRxiv, accessed January 23, 2026, [https://www.biorxiv.org/content/10.1101/2024.04.09.588624v2.full-text](https://www.biorxiv.org/content/10.1101/2024.04.09.588624v2.full-text)  
31. Metabolite accumulation from oral NMN supplementation drives aging-specific kidney inflammation | bioRxiv, accessed January 23, 2026, [https://www.biorxiv.org/content/10.1101/2024.04.09.588624v1.full-text](https://www.biorxiv.org/content/10.1101/2024.04.09.588624v1.full-text)  
32. Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging, accessed January 23, 2026, [https://www.aginganddisease.org/EN/10.14336/AD.2023.0519-1](https://www.aginganddisease.org/EN/10.14336/AD.2023.0519-1)  
33. Effect of NMN on expression of genes involved in mitochondrial... \- ResearchGate, accessed January 23, 2026, [https://www.researchgate.net/figure/Effect-of-NMN-on-expression-of-genes-involved-in-mitochondrial-biogenesis-fat-transport\_fig5\_340265399](https://www.researchgate.net/figure/Effect-of-NMN-on-expression-of-genes-involved-in-mitochondrial-biogenesis-fat-transport_fig5_340265399)  
34. NAD World 3.0: the importance of the NMN transporter and eNAMPT ..., accessed January 23, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11772665/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11772665/)

[image1]: <data:image/png;base64,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>

[image2]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAwAAAAYCAYAAADOMhxqAAABFUlEQVR4XtXSvUpDQRCG4REN+IuCIliIENNZWEVRgoWdhY3W2oiXkAQlXWpBTGNhijQK3oAWFrkFA1ZeQAo7sdd3ziQ6OyFgmw+eZnazu2cmIiOVHPZwiMWwNpAiHnGGU7ziKNnhsoF7zLtaFS+YcbUsU7hFIdQv0cZsqMsOKqGmhzzjGmNhTWooYRIrWMCx2DesuX1Z9H0N7KKL754vbLl9v8njSuxaPVlvmEYdD5j422o5wHksis1Bb9QDk1yI9T9G+/+JTV/sv3/JF3u5wZuENb1OJzvni2QV72LfkbRU3/+BbVfT/t/hSdKpZ9H+n4hNs4UmOiiL/TCJf/84lsX+nQNT7cf3/18Z1v+h2cd6LI5QfgDG5CT71hATlgAAAABJRU5ErkJggg==>

[image3]: <data:image/png;base64,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>

[image4]: <data:image/png;base64,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>

[image5]: <data:image/png;base64,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>

[image6]: <data:image/png;base64,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>

[image7]: <data:image/png;base64,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>

[image8]: <data:image/png;base64,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>

[image9]: <data:image/png;base64,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>